Nate, 55, a smoker, has seen three dermatologists for a rash that seems to be resistant to various treatments. He has complained that he has had a chronic bumpy and painful rash with pustules ...

The US Food and Drug Administration has approved denileukin diftitox-cxdl (Lymphir, Citius Pharmaceuticals) for adults with relapsed or refractory stage 1-3 cutaneous T-cell lymphoma after at least ...

Extracorporeal photochemotherapy (ECP), also called photopheresis, is a type of pheresis in which aliquots of the patient's blood are removed, treated with a photosensitizing agent, and subjected to ...

The therapeutic landscape for cutaneous T-cell lymphoma (CTCL) is undergoing a significant shift with the emergence of denileukin diftitox (Lymphir), the first systemic treatment ...

Tattoos may increase the risk of developing lymphoma and skin cancer, a recent study suggests. "We can see that ink particles accumulate in the lymph nodes, and we suspect that the body perceives them ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved the novel immunotherapy denileukin diftitox-cxdl for treatment of certain patients with ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab-treated patients with AD were 4.1003 times more likely to develop cutaneous T-cell lymphoma vs. those ...

PRINCETON, N.J., Dec. 1, 2023 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare ...

The pleural effusion that was initially drained recurred after two weeks but subsequently resolved on follow‑up imaging as part of the patient’s response to chemotherapy. Repeat LDH measurement was ...

A new study by researchers at Karolinska Institutet and Karolinska University Hospital shows that patients diagnosed with the rare skin cancers mycosis fungoides and Sézary syndrome face a ...